肺癌的基因组学和蛋白组学研究演示文稿.ppt

通过基因组学及蛋白组学指导个体化治疗;通过基因组学及蛋白组学完成个体化治疗;已应用的分子标记物:乳腺癌 ER 水平;我们能否应用分子标记物 指导NSCLC的治疗?;LACE Meta-AnalysisJ-P. Pignon et al. J Clin Oncol 26:3552, 2008;我们能否应用分子标记物 指导NSCLC的治疗?;IB/II期 NSCLC的辅助化疗T. Winton et al. NEJM 352:2589, 2005;IB/II期 NSCLC的辅助化疗M-S. Tsao et al. J Clin Oncol 25:5240, 2007;IB/II期 NSCLC的辅助化疗M-S. Tsao et al. J Clin Oncol 25:5240, 2007;辅助治疗中的 预后 预测分子;我们能否应用基因信号 指导 NSCLC的治疗?;基因组学与预后A. Potti, et al. NEJM 355:570, 2006; IA期 NSCLC的辅助化疗A. Potti et al. NEJM 355:570, 2006;NSCLC中的分子标记物Sun Yang. Cancer Epidemiol Biomarkers Prev 15:2063, 2006;基因还是分期?Sun Yang. Cancer Epidemiol Biomarkers Prev 15:2063, 2006;选择基因还是临床标记?Are Gene Signatures Redundant?;NSCLC 治疗的临床预后预测因素;All Stages; P=0.002;从基因到蛋白;“Good”;蛋白组学预测结局F. Taguchi et al. JNCI 99:838, 2007;治疗前预测;应用基因标记指导 NSCLC患者的化疗;Ions;已切除的 II/III 期NSCLC蛋白组学预测分级;分子标记物临床医生的问题;我们能否应用分子标记物指导NSCLC的治疗?;NSCLC中分子标记物总结;;三基因预后分类S.K. Lau et al. J Clin Oncol 25:5562, 2007;ERCC1 预后因子G. Simon et al. Chest 127:978, 2005;ERCC1 与 特异性临床预测因子的关系;从基因到蛋白;基因组学还是蛋白组学?;“Good”;已切除的 I 期NSCLC蛋白组学预测分类;Has helped improve our understanding of the histological heterogeneity of NSCLC. Has identified potential biomarkers gene signatures for classifying patients with significantly different survival outcomes. However, the performance general applicability of published classifiers has not been easy to establish because of small numbers of subjects examined inclusion of heterogeneous tumor types. Furthermore, there have not been uniform criteria for sample inclusion, annotation, sample processing data analyses. ;Gene Expression-based Survival Prediction in Lung AdenocarcinomaK. Shedden et al. Nat Med 14:822, 2008;什么样的标记物是合适的?;什么样的标记物是合适的?